Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes
NCT02048189 · Centre Hospitalier Universitaire Dijon · PHASE4 · terminated · last registry update 2024-02-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “recruitment difficulties” | – | Registry record, Centre Hospitalier Universitaire Dijon |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against INSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-02-20Results posted on the registry: Novo Nordisk A/S, Insulin degludec + Insulin Icodec (NCT04770532)
- 2025-01-17Results posted on the registry: Novo Nordisk A/S, IcoSema + Semaglutide 1 mg (NCT05259033)
- 2025-01-10Phase 3 first posted: Gan & Lee Pharmaceuticals., GZR4 + insulin degludec (NCT06767748)
- 2024-12-04Results posted on the registry: Novo Nordisk A/S, Insulin icodec + Placebo insulin icodec (NCT04795531)
- 2024-11-20Also stopped (terminated): Astellas Pharma Inc, OSI-906 + Placebo (NCT01101906)
- 2024-10-30Results posted on the registry: Sanofi, Insulin glargine/Lixisenatide + IDegAsp (NCT05413369)
- 2024-10-18Results posted on the registry: Mannkind Corporation, Afrezza (insulin human) Inhalation Powder + insulin degludec (NCT05243628)
- 2024-10-01Phase 3 first posted: Loyola University, Insulin glargine + insulin NPH (NCT06619301)
- 2024-09-19Phase 3 first posted: University of Campinas, Brazil, NPH insulin 50 IU/mL eye drops + 0.5% methylcellulose eye drops (placebo) (NCT06601101)
- 2024-09-05Results posted on the registry: Sanofi, Insulin glargine 300 U/mL + Insulin degludec 100 U/mL (NCT05552859)
- 2024-08-19Phase 3 first posted: Tonghua Dongbao Pharmaceutical Co.,Ltd, Insulin Degludec/liraglutide Injection + XULTOPHY® (NCT06559722)
- 2024-07-29Results posted on the registry: The Cleveland Clinic, Semaglutide + Insulin Degludec (NCT04538352)
- 2024-04-02Phase 3 first posted: Novo Nordisk A/S, Insulin icodec + Insulin glargine (NCT06340854)
- 2024-03-20Results posted on the registry: Novo Nordisk A/S, Faster aspart + Insulin aspart (NCT04588259)
- 2024-02-28Results posted on the registry: University of Washington, Insulin Degludec + Insulin Glargine (NCT04623086)
- 2024-02-21Phase 3 first posted: Novo Nordisk A/S, IcoSema + Insulin glargine (NCT06269107)
- 2024-01-24Results posted on the registry: University at Buffalo, Dapagliflozin + Insulin (NCT02518945)
- 2023-11-02Also stopped (terminated): Charles Drew University of Medicine and Science, Insulin glargine at bedtime instead of NPH + NPH twice-daily (NCT00687453)
- 2023-11-01Phase 3 first posted: Sling Therapeutics, Inc., linsitinib (NCT06112340)
- 2023-09-18Results posted on the registry: Corewell Health West, insulin glulisine + insulin aspart (NCT00913497)
- 2023-09-08Results posted on the registry: Emory University, IDegLira + Insulin Degludec (U-100) (NCT03737240)
- 2023-08-14Also stopped (terminated): Novo Nordisk A/S, insulin detemir + insulin NPH (NCT00506662)
- 2023-04-21Phase 3 first posted: Novo Nordisk A/S, Insulin Icodec (NCT05823948)
- 2023-04-14Phase 3 first posted: Novo Nordisk A/S, Insulin Icodec + Semaglutide (NCT05813912)
- 2023-04-07Phase 3 first posted: Sunshine Lake Pharma Co., Ltd., Insulin Degludec and Insulin Aspart (NCT05802862)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision